STACK_RATINGSby NERD_PROTOCOLS
< LEADERBOARD/s/copperMinerals

Copper

Also sold as: Elemental copper · Copper gluconate · Copper bisglycinate

An essential trace mineral needed for iron handling, connective tissue and nervous-system function. Correcting a documented deficiency differs fundamentally from supplementing copper-replete people for energy, hair color or memory.

Focus

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

FocusNo established evidence
  • Focus: Cognitive benefit is unestablished; copper-dysregulation reviews do not demonstrate a copper-supplement focus benefit or a negative cognition RCT.

REALITY CHECK // Copper helps when copper deficiency is actually present; it is not a proven remedy for everyone with fatigue, gray hair or brain fog. Zinc-induced deficiency can be serious and neurological recovery may be incomplete. Marketing claims of premium-chelate superiority lack strong human head-to-head support.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Try a common label:
The label number is the…

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE
Preparation-specific research
No universal trial-proven supplemental dose for healthy adults is established. The dossier discusses1–2 mg elemental maintenance labels and consumer2/3/6 mg amounts, not a validated treatment protocol. Deficiency correction dose and route require clinical assessment.
02 // TIMING_&_MATRIX
Matrix and timing
A meal may improve tolerance. Dose spacing cannot fully prevent zinc-induced copper depletion; use label-declared elemental amounts.
03 // EVALUATION_WINDOW
Trial observation window
Deficiency blood-count correction occurs over weeks to months; neurologic recovery may remain incomplete. No general cognition trial window.
04 // SAFETY_&_QUALITY_GATE
Safety and quality
Avoid blind dosing in Wilson disease and impaired biliary clearance. US10 mg/day is total elemental exposure, including food.

UPPER LIMIT // The dossier cites a historical European adult5 mg/day ceiling and US adult UL10 mg/day, both total elemental copper exposure. The contemporary European classification and scope need live primary-document verification, so the EFSA numeric gate is withheld; the cited US10 mg total-intake UL is retained. Requirements around0.9 mg/day are not an UL.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

Copper replacement corrects deficiency-related anemia and neutropenia in clinical reports, especially after malabsorption or excess zinc. Neurologic recovery can be incomplete. Healthy/replete adult trials show null or mixed cardiovascular/bone markers rather than a general wellness benefit.

Mechanism

Copper supports ceruloplasmin/hephaestin iron transport, cytochrome oxidase and lysyl oxidase. Excess zinc induces intestinal metallothionein, trapping copper and increasing losses; mechanisms do not establish hair repigmentation or cognitive benefits.

Typical studied dose

No universal trial-proven supplemental dose for healthy adults is established. The dossier discusses1–2 mg elemental maintenance labels and consumer2/3/6 mg amounts, not a validated treatment protocol. Deficiency correction dose and route require clinical assessment.

Upper limit

The dossier cites a historical European adult5 mg/day ceiling and US adult UL10 mg/day, both total elemental copper exposure. The contemporary European classification and scope need live primary-document verification, so the EFSA numeric gate is withheld; the cited US10 mg total-intake UL is retained. Requirements around0.9 mg/day are not an UL.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Copper

Not enough stack data yet. A combination with Copper appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on labelActive contentStudied range / dayAbsorption & GI toleranceVerdict
Copper sulfate pentahydrate (CuSO4·5H2O)
Best for: Only compare when the pentahydrate identity is explicit.
 25.45% elemental / active no comparable trial range Soluble clinical copper salt; robust human superiority comparisons are sparse.
May cause nausea, especially fasting.		 Caution [FORM // NO_VALIDATED_RANGE]
Stoichiometric elemental copper fraction is about25.45%; the source average32.5% incorrectly mixed hydration states. Trial interval unavailable.
Anhydrous copper sulfate (CuSO4)
Best for: Only compare explicitly anhydrous material.
 39.81% elemental / active no comparable trial range Soluble copper salt; clinical form choice is secondary to indication and elemental dose.
Potential gastric irritation.		 Caution [FORM // NO_VALIDATED_RANGE]
About39.81% copper by molecular mass. Never use this factor for pentahydrate.
Copper gluconate
Best for: Check the label-declared elemental amount.
 14% elemental / active no comparable trial range No reliable human head-to-head superiority established.
Digestive tolerance varies; stop for persistent symptoms.		 Caution [FORM // NO_VALIDATED_RANGE]
Approximately14% elemental copper is a chemical composition estimate, not an absorption rate. No established trial interval.
Copper bisglycinate / glycinate
Best for: Use manufacturer-declared elemental copper; commercial chelate composition varies.
 Unstandardized: active content unknown no comparable trial range No reliable human head-to-head superiority established.
Digestive tolerance varies; stop for persistent symptoms.		 Caution [FORM // NO_VALIDATED_RANGE]
No verified product-specific elemental fraction supplied. Compound-to-elemental conversion disabled;100% copper must not be inferred.

Common label traps

  • TRAP_01 // EVERY ZINC USER NEEDS A FIXED COPPER RATIO
    Need depends on dose, duration, food and clinical status. A fixed ratio cannot diagnose deficiency or prevent all toxicity.
  • TRAP_02 // COPPER REVERSES GRAY HAIR
    Tyrosinase requires copper, but no human trial here establishes repigmentation in copper-replete people.
  • TRAP_03 // PREMIUM CHELATE MEANS BETTER OUTCOMES
    Human head-to-head evidence among sulfate, gluconate and bisglycinate is sparse.
  • TRAP_04 // COPPER TREATS GENERAL FATIGUE OR DEPRESSION
    Deficiency correction is a specific clinical context; general benefit is unestablished.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

  • DEFICIENCY ANEMIA / NEUTROPENIA Moderate · benefit
    Case reports, series and reviews document hematologic correction after oral/IV repletion in confirmed deficiency. This is not an RCT-proven benefit for copper-replete people.
    PMID 29959467 PMID 38130564 PMID 6410510 PMID 36089206 PMID 39610429
  • ZINC-INDUCED DEFICIENCY Moderate · benefit
    Repeated reports and mechanism support zinc-induced copper depletion and hematologic recovery after clinically guided correction.
    PMID 38520630 PMID 40700102 PMID 37640593 PMID 36761368 PMID 37736439 PMID 15762288 PMID 2407097
  • DEFICIENCY MYELOPATHY Limited · benefit
    Replacement often stabilizes progression but complete neurologic recovery is not assured; can resemble B12 deficiency and needs medical work-up.
    PMID 20232210 PMID 37851293 PMID 31837157
  • CARDIOVASCULAR MARKERS Limited · no benefit
    Replete adult RCTs do not establish consistent lipid/CVD-marker benefit; epidemiology is not a supplementation indication.
    PMID 9439530 PMID 22444781 PMID 16115357
  • BONE DENSITY Limited · no benefit
    Postmenopausal trial findings favor zinc-status explanations rather than a clear independent copper benefit; collagen-crosslinking biology is not proof of increased BMD.
    PMID 21733304 PMID 8027856 PMID 34210051
  • ALZHEIMER / COPPER DYSREGULATION No established evidence
    Reviews concern copper dyshomeostasis and possible risk mechanisms, not proof that oral copper prevents dementia.
    PMID 28889269 PMID 30352697 PMID 34313926
  • HAIR REPIGMENTATION No established evidence
    No supporting human oral-supplement trial is supplied for copper-replete people.
  • WOUND / SKIN APPLICATIONS Limited · benefit
    Dressings and GHK-Cu research concern topical or preclinical applications; they do not establish oral copper efficacy for skin healing in replete adults.
    PMID 40149539 PMID 26236730

Reader questions

How much copper should accompany zinc?

No universal safe ratio follows from this dossier. Review zinc exposure, diet and need; serum copper and ceruloplasmin need clinical interpretation, especially with estrogen or inflammation.

Is6 mg a reasonable daily dose?

That exceeds the historical European5 mg figure cited in the dossier before food is counted. Absence of a confirmed deficiency is not a reason to approach the US10 mg total-intake UL; seek individualized advice.

Which form is best?

No robust human comparison proves bisglycinate superior. Elemental dose, hydration state, indication and tolerance matter more than premium marketing.

Could brain fog or fatigue be copper deficiency?

Possibly in a risk context such as malabsorption or excessive zinc, but symptoms are nonspecific. Neurologic symptoms or anemia need evaluation rather than a supplement trial.

How can I avoid vomiting after copper?

Fasting can worsen nausea, but repeated vomiting is a stop signal rather than something to mask. Review total elemental exposure and seek care if severe or persistent.

Stack interactions

  • Danger Long-term zinc [CAUTION // CLINICAL_CONTEXT]
    Repeated clinical reports link high-dose zinc, often around50 mg/day or more but sometimes lower, to copper-deficiency anemia/neuropathy. Timing separation alone is not a complete solution.
    PMID 38520630 PMID 37640593 PMID 15762288 PMID 2407097
  • Danger Wilson-disease chelators / therapeutic zinc [CAUTION // CLINICAL_CONTEXT]
    Penicillamine, trientine and zinc are used to reduce copper; unsupervised copper supplementation can oppose treatment. Deficiency during treatment still needs specialist correction.
    PMID 21449011 PMID 37851293
  • Caution High-dose iron, vitamin C, calcium or molybdenum [CAUTION // CLINICAL_CONTEXT]
    Competition or antagonism is mechanistically plausible, most relevant to excessive exposure. The dossier does not supply a quantified ordinary-diet interaction risk.
  • Caution Estrogen and acid-suppressing medicines [CAUTION // CLINICAL_CONTEXT]
    Estrogen-related copper/ceruloplasmin elevation affects interpretation; a PPI-malabsorption contribution is lower-certainty in this dossier. Neither automatically indicates extra copper.

Red flags: interactions and who should avoid it

Interactions

Long-term high-dose zinc can cause deficiency; merely separating doses does not remove the chronic metallothionein effect. Copper chelators and therapeutic zinc in Wilson disease intentionally lower copper. Iron, very high vitamin C/calcium and molybdenum concerns are mostly mechanistic; estrogen can affect interpretation of copper/ceruloplasmin results.

Avoid or ask a doctor first if

Do not supplement in Wilson disease except specialist-directed circumstances. Liver disease/cholestasis can impair biliary elimination. Persistent vomiting, abdominal pain, jaundice or neurologic symptoms require assessment. Pregnancy, children and suspected deficiency need individualized care rather than blind zinc:copper ratios.

Sources (PubMed, 16)

  1. Copper deficiency anemia: review article.
    PMID 29959467 · 2018 · narrative review
    Clinical deficiency-anemia review, not healthy-population supplementation evidence.
  2. Copper Deficiency: An Overlooked Diagnosis.
    PMID 38130564 · 2023 · clinical study / report
    Clinical deficiency diagnosis report.
  3. Copper deficiency anemia due to zinc supplementation in a chronic hemodialysis patient.
    PMID 38520630 · 2024 · clinical study / report
    Zinc-associated copper-deficiency anemia in hemodialysis.
  4. Severe copper deficiency anemia caused by zinc supplement use.
    PMID 37640593 · 2023 · clinical study / report
    Severe zinc-supplement-associated copper-deficiency anemia.
  5. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination.
    PMID 15762288 · 2005 · clinical study / report
    Three zinc-induced deficiency cases identified from marrow findings.
  6. Zinc toxicity.
    PMID 2407097 · 1990 · narrative review
    Zinc toxicity review and copper-depletion mechanism.
  7. Copper deficiency myelopathy.
    PMID 20232210 · 2010 · narrative review
    Deficiency myelopathy and limited recovery.
  8. Neurological complications due to copper deficiency in the context of Wilson disease treatment: a case report with long-term follow-up and review of the literature.
    PMID 37851293 · 2024 · clinical study / report
    Neurological complications during Wilson-disease treatment.
  9. Copper supplementation of adult men: effects on blood copper enzyme activities and indicators of cardiovascular disease risk.
    PMID 9439530 · 1997 · randomized controlled trial
    Replete-men supplementation and cardiovascular enzyme/risk markers.
  10. A randomized trial of copper supplementation effects on blood copper enzyme activities and parameters related to cardiovascular health.
    PMID 22444781 · 2012 · randomized controlled trial
    RCT of copper and cardiovascular-related parameters, without established general benefit.
  11. Effect of copper supplementation on indices of copper status and certain CVD risk markers in young healthy women.
    PMID 16115357 · 2005 · randomized controlled trial
    Healthy-women copper-status/CVD-marker trial.
  12. Reported zinc, but not copper, intakes influence whole-body bone density, mineral content and T score responses to zinc and copper supplementation in healthy postmenopausal women.
    PMID 21733304 · 2011 · randomized controlled trial
    Postmenopausal bone responses related to reported zinc rather than copper intake.
  13. Copper and Alzheimer's Disease.
    PMID 28889269 · 2017 · narrative review
    Copper/Alzheimer mechanistic review, not oral supplementation benefit.
  14. Copper and Zinc Dysregulation in Alzheimer's Disease.
    PMID 30352697 · 2018 · narrative review
    Copper/zinc dysregulation review.
  15. Copper.
    PMID 10382557 · 1999 · narrative review
    Copper toxicology review.
  16. Deadly excess copper.
    PMID 38959622 · 2024 · narrative review
    Excess-copper toxicity mechanisms.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this